Entera Bio Q1 net loss $2.0M; cash $9.2M; FDA catalyst path for EB613

Entera Bio Ltd.

2024-Q1 EPS reported $0.05

Q1 net loss $2.0M ($0.05 per share) vs $2.2M ($0.08) in Q1 2023.
Cash $9.2M at March 31, 2024; runway into Q3 2025.
R&D expenses $0.7M (down from $0.9M); G&A flat at $1.3M.
FDA to rule on BMD as surrogate for fractures within 10 months – key catalyst for EB613 Phase 3.
Oral GLP-2 tablets showed 10-fold higher plasma exposure vs teduglutide; OXM PK data expected mid-2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Entera Bio Ltd. reported the quarter ended March 31, 2024 results: net income $2.0 million, EPS $0.05 per ordinary share (basic and diluted).

Period: the quarter ended March 31, 2024
Net income: $2.0 million
EPS: $0.05 per ordinary share (basic and diluted)
Result: reported results

Exact text from the filing

Net loss was $2.0 million, or $0.05 per ordinary share (basic and diluted), for the period ended March 31, 2024, as compared to $2.2 million, or $0.08 per ordinary share (basic and diluted), for the period ended March 31, 2023.

View on SEC.gov

1362 earnings releases filed in the last 30 days. Browse all earnings releases →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-24-001681

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.